$ARGS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARGOS THERAPEUTICS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ARGOS THERAPEUTICS INC. Get notifications about new insider transactions in ARGOS THERAPEUTICS INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 25 2018 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | Chief Executive Off ... | Sell | D | 0.00 | 67,887 | 0 | 25,450 | 93.3 K to 25.5 K (-72.73 %) |
Apr 25 2018 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | Vice President and ... | Sell | D | 0.00 | 22,629 | 0 | 9,697 | 32.3 K to 9.7 K (-70.00 %) |
Apr 25 2018 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President of F ... | Sell | D | 0.00 | 22,629 | 0 | 11,776 | 34.4 K to 11.8 K (-65.77 %) |
Apr 25 2018 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | CSO and Vice Presid ... | Sell | D | 0.00 | 27,150 | 0 | 20,056 | 47.2 K to 20.1 K (-57.51 %) |
Apr 02 2018 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | Vice President and ... | Grant | A | 0.00 | 22,629 | 0 | 32,326 | 9.7 K to 32.3 K (+233.36 %) |
Apr 02 2018 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | Vice President and ... | Grant | A | 0.00 | 22,629 | 0 | 32,326 | 9.7 K to 32.3 K (+233.36 %) |
Mar 30 2018 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President of F ... | Grant | A | 0.00 | 22,629 | 0 | 34,405 | 11.8 K to 34.4 K (+192.16 %) |
Mar 30 2018 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | CSO and Vice Presid ... | Grant | A | 0.00 | 27,150 | 0 | 47,206 | 20.1 K to 47.2 K (+135.37 %) |
Mar 30 2018 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | Chief Executive Off ... | Grant | A | 0.00 | 67,887 | 0 | 93,337 | 25.5 K to 93.3 K (+266.75 %) |
Jan 12 2018 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President of F ... | Sell | S | 0.16 | 64,329 | 10,595 | 230,981 | 295.3 K to 231 K (-21.78 %) |
Jan 12 2018 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | CSO and Vice Presid ... | Sell | S | 0.16 | 100,250 | 16,501 | 399,990 | 500.2 K to 400 K (-20.04 %) |
Jan 12 2018 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | President, CEO | Sell | S | 0.16 | 124,987 | 20,573 | 510,046 | 635 K to 510 K (-19.68 %) |
Jan 12 2018 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | Vice President and ... | Sell | S | 0.16 | 104,435 | 17,200 | 193,959 | 298.4 K to 194 K (-35.00 %) |
Jan 05 2018 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | President, CEO | Sell | S | 0.16 | 114,702 | 18,719 | 635,033 | 749.7 K to 635 K (-15.30 %) |
Jan 05 2018 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | Vice President and ... | Sell | S | 0.16 | 101,228 | 16,541 | 298,394 | 399.6 K to 298.4 K (-25.33 %) |
Jan 05 2018 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | CSO and Vice Presid ... | Sell | S | 0.16 | 92,001 | 15,061 | 500,240 | 592.2 K to 500.2 K (-15.53 %) |
Jan 05 2018 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President of F ... | Sell | S | 0.16 | 59,072 | 9,658 | 295,310 | 354.4 K to 295.3 K (-16.67 %) |
Jan 05 2018 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | President, CEO | Sell | S | 0.16 | 114,702 | 18,719 | 635,033 | 749.7 K to 635 K (-15.30 %) |
Nov 02 2017 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Sell | J | 795.96 | 99,495 | 79,194,040 | 13,142,784 | 13.2 M to 13.1 M (-0.75 %) |
Sep 28 2017 | ARGS | ARGOS THERAPEUTICS ... | MORRISON RICHARD G | Director | Option Exercise | A | 0.17 | 30,000 | 5,100 | 30,000 | |
Aug 31 2017 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President of F ... | Grant | A | 0.00 | 320,683 | 0 | 354,382 | 33.7 K to 354.4 K (+951.61 %) |
Aug 31 2017 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | VP and Chief Financ ... | Grant | A | 0.00 | 395,664 | 0 | 399,622 | 4 K to 399.6 K (+9,996.56 %) |
Aug 31 2017 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Science Offic ... | Grant | A | 0.00 | 499,445 | 0 | 592,241 | 92.8 K to 592.2 K (+538.22 %) |
Aug 31 2017 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | Chief Executive Off ... | Grant | A | 0.00 | 622,685 | 0 | 749,735 | 127.1 K to 749.7 K (+490.11 %) |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President Fina ... | Option Exercise | A | 5.05 | 50,000 | 252,500 | 50,000 | |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President Fina ... | Grant | A | 0.00 | 3,694 | 0 | 33,699 | 30 K to 33.7 K (+12.31 %) |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Option Exercise | A | 4.85 | 85,000 | 412,250 | 85,000 | |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Grant | A | 0.00 | 4,464 | 0 | 47,248 | 42.8 K to 47.2 K (+10.43 %) |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | VP & Chief Financia ... | Option Exercise | A | 4.85 | 105,000 | 509,250 | 105,000 | |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | VP & Chief Financia ... | Grant | A | 0.00 | 3,958 | 0 | 3,958 | 0 to 4 K |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | ALLEN LEE F MD PhD | Chief Medical Offic ... | Option Exercise | A | 4.85 | 85,000 | 412,250 | 85,000 | |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | ALLEN LEE F MD PhD | Chief Medical Offic ... | Grant | A | 0.00 | 7,378 | 0 | 7,378 | 0 to 7.4 K |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | Chief Executive Off ... | Option Exercise | A | 4.85 | 386,212 | 1,873,128 | 386,212 | |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | Chief Executive Off ... | Grant | A | 0.00 | 17,430 | 0 | 127,050 | 109.6 K to 127.1 K (+15.90 %) |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Science Offic ... | Option Exercise | A | 4.85 | 185,000 | 897,250 | 185,000 | |
Jan 23 2017 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Science Offic ... | Grant | A | 0.00 | 16,753 | 0 | 92,796 | 76 K to 92.8 K (+22.03 %) |
Jan 20 2017 | ARGS | ARGOS THERAPEUTICS ... | Krol Igor | Director | Option Exercise | A | 4.85 | 9,500 | 46,075 | 9,500 | |
Jan 20 2017 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Option Exercise | A | 4.85 | 9,500 | 46,075 | 9,500 | |
Jan 20 2017 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Option Exercise | A | 4.85 | 9,500 | 46,075 | 9,500 | |
Jan 20 2017 | ARGS | ARGOS THERAPEUTICS ... | Carey Robert | Director | Option Exercise | A | 4.85 | 9,500 | 46,075 | 9,500 | |
Jan 04 2017 | ARGS | ARGOS THERAPEUTICS ... | Carey Robert | Director | Grant | A | 0.00 | 2,351 | 0 | 8,206 | 5.9 K to 8.2 K (+40.15 %) |
Jan 04 2017 | ARGS | ARGOS THERAPEUTICS ... | SNYDERMAN RALPH | Director | Grant | A | 0.00 | 573 | 0 | 573 | 0 to 573 |
Jan 04 2017 | ARGS | ARGOS THERAPEUTICS ... | Krol Igor | Director | Grant | A | 0.00 | 1,785 | 0 | 3,874 | 2.1 K to 3.9 K (+85.45 %) |
Jan 04 2017 | ARGS | ARGOS THERAPEUTICS ... | Mtibelishvily Irackly | Director | Grant | A | 0.00 | 395 | 0 | 14,895 | 14.5 K to 14.9 K (+2.72 %) |
Jan 04 2017 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Grant | A | 0.00 | 3,571 | 0 | 12,680 | 9.1 K to 12.7 K (+39.20 %) |
Dec 15 2016 | ARGS | ARGOS THERAPEUTICS ... | Mtibelishvily Irackly | Director | Option Exercise | A | 4.60 | 30,000 | 138,000 | 30,000 | |
Dec 13 2016 | ARGS | ARGOS THERAPEUTICS ... | SNYDERMAN RALPH | Director | Option Exercise | A | 4.90 | 30,000 | 147,000 | 30,000 | |
Oct 13 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.73 | 21,000 | 99,330 | 13,242,279 | 13.2 M to 13.2 M (+0.16 %) |
Oct 13 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.81 | 2,640 | 12,698 | 13,221,279 | 13.2 M to 13.2 M (+0.02 %) |
Oct 13 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.85 | 900 | 4,365 | 13,218,639 | 13.2 M to 13.2 M (+0.01 %) |
Oct 13 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.69 | 7,164 | 33,599 | 13,217,739 | 13.2 M to 13.2 M (+0.05 %) |
Oct 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.70 | 11,308 | 53,148 | 13,210,875 | 13.2 M to 13.2 M (+0.09 %) |
Oct 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.71 | 30,232 | 142,393 | 13,199,567 | 13.2 M to 13.2 M (+0.23 %) |
Oct 03 2016 | ARGS | ARGOS THERAPEUTICS ... | Carey Robert | Director | Grant | A | 0.00 | 2,263 | 0 | 5,855 | 3.6 K to 5.9 K (+63.00 %) |
Oct 03 2016 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Grant | A | 0.00 | 2,263 | 0 | 50,955 | 48.7 K to 51 K (+4.65 %) |
Oct 03 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Grant | A | 0.00 | 2,263 | 0 | 5,057 | 2.8 K to 5.1 K (+80.99 %) |
Oct 03 2016 | ARGS | ARGOS THERAPEUTICS ... | Krol Igor | Director | Grant | A | 0.00 | 1,760 | 0 | 2,089 | 329 to 2.1 K (+534.95 %) |
Oct 03 2016 | ARGS | ARGOS THERAPEUTICS ... | Petrov Andrei Vladimirovich | Director | Grant | A | 0.00 | 2,137 | 0 | 10,530 | 8.4 K to 10.5 K (+25.46 %) |
Oct 03 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Grant | A | 0.00 | 3,521 | 0 | 9,109 | 5.6 K to 9.1 K (+63.01 %) |
Sep 30 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.60 | 15,100 | 69,460 | 13,169,335 | 13.2 M to 13.2 M (+0.11 %) |
Sep 30 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.54 | 28,518 | 129,472 | 13,154,235 | 13.1 M to 13.2 M (+0.22 %) |
Sep 21 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.77 | 41,259 | 196,805 | 13,125,717 | 13.1 M to 13.1 M (+0.32 %) |
Sep 21 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.76 | 5,580 | 26,561 | 13,084,458 | 13.1 M to 13.1 M (+0.04 %) |
Sep 20 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.78 | 36,632 | 175,101 | 13,078,578 | 13 M to 13.1 M (+0.28 %) |
Sep 20 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.76 | 15,880 | 75,589 | 13,041,946 | 13 M to 13 M (+0.12 %) |
Sep 07 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.78 | 16,977 | 81,150 | 13,026,066 | 13 M to 13 M (+0.13 %) |
Aug 29 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.57 | 55,224 | 252,374 | 13,009,089 | 13 M to 13 M (+0.43 %) |
Aug 25 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.55 | 57,772 | 262,863 | 12,953,865 | 12.9 M to 13 M (+0.45 %) |
Aug 25 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.36 | 9,599 | 41,852 | 12,896,093 | 12.9 M to 12.9 M (+0.07 %) |
Aug 23 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.26 | 21,950 | 93,507 | 12,886,494 | 12.9 M to 12.9 M (+0.17 %) |
Aug 23 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 4.23 | 53,524 | 226,407 | 12,864,544 | 12.8 M to 12.9 M (+0.42 %) |
Aug 04 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Option Exercise | P | 5.50 | 1,159,090 | 6,374,995 | 1,159,090 | |
Aug 04 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Buy | P | 0.00 | 1,545,454 | 0 | 6,199,961 | 4.7 M to 6.2 M (+33.20 %) |
Aug 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Option Exercise | P | 5.50 | 1,772,727 | 9,749,999 | 1,772,727 | |
Aug 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 0.00 | 2,363,636 | 0 | 12,811,020 | 10.4 M to 12.8 M (+22.62 %) |
Aug 04 2016 | ARGS | ARGOS THERAPEUTICS ... | ForArgos B.V. | 10% Owner | Option Exercise | P | 5.50 | 1,159,090 | 6,374,995 | 1,159,090 | |
Aug 04 2016 | ARGS | ARGOS THERAPEUTICS ... | ForArgos B.V. | 10% Owner | Buy | P | 0.00 | 1,545,454 | 0 | 3,749,817 | 2.2 M to 3.7 M (+70.11 %) |
Jul 13 2016 | ARGS | ARGOS THERAPEUTICS ... | Katz Richard D | VP & Chief Financia ... | Option Exercise | A | 6.30 | 300,000 | 1,890,000 | 300,000 | |
Jul 12 2016 | ARGS | ARGOS THERAPEUTICS ... | ALLEN LEE F MD PhD | Chief Medical Offic ... | Option Exercise | A | 6.30 | 83,373 | 525,250 | 83,373 | |
Jul 05 2016 | ARGS | ARGOS THERAPEUTICS ... | Carey Robert | Director | Grant | A | 0.00 | 1,835 | 0 | 3,592 | 1.8 K to 3.6 K (+104.44 %) |
Jul 05 2016 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Grant | A | 0.00 | 1,835 | 0 | 48,692 | 46.9 K to 48.7 K (+3.92 %) |
Jul 05 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Grant | A | 0.00 | 1,427 | 0 | 2,794 | 1.4 K to 2.8 K (+104.39 %) |
Jul 05 2016 | ARGS | ARGOS THERAPEUTICS ... | Krol Igor | Director | Grant | A | 0.00 | 329 | 0 | 329 | 0 to 329 |
Jul 05 2016 | ARGS | ARGOS THERAPEUTICS ... | Petrov Andrei Vladimirovich | Director | Grant | A | 0.00 | 1,733 | 0 | 8,393 | 6.7 K to 8.4 K (+26.02 %) |
Jul 05 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Grant | A | 0.00 | 2,854 | 0 | 5,588 | 2.7 K to 5.6 K (+104.39 %) |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Option Exercise | P | 5.35 | 2,008,726 | 10,746,684 | 2,008,726 | |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 0.00 | 2,678,301 | 0 | 10,447,384 | 7.8 M to 10.4 M (+34.47 %) |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Option Exercise | P | 5.35 | 991,964 | 5,307,007 | 991,964 | |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Buy | P | 0.00 | 1,322,618 | 0 | 4,654,507 | 3.3 M to 4.7 M (+39.70 %) |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Option Exercise | P | 5.35 | 206,659 | 1,105,626 | 206,659 | |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Buy | P | 0.00 | 275,545 | 0 | 1,930,333 | 1.7 M to 1.9 M (+16.65 %) |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | ForArgos B.V. | 10% Owner | Option Exercise | P | 5.35 | 991,964 | 5,307,007 | 991,964 | |
Jul 01 2016 | ARGS | ARGOS THERAPEUTICS ... | ForArgos B.V. | 10% Owner | Buy | P | 0.00 | 1,322,618 | 0 | 2,204,363 | 881.7 K to 2.2 M (+150.00 %) |
Jun 15 2016 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Option Exercise | A | 7.41 | 80,000 | 592,800 | 80,000 | |
Jun 15 2016 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Grant | A | 0.00 | 7,287 | 0 | 40,996 | 33.7 K to 41 K (+21.62 %) |
Jun 15 2016 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President of F ... | Option Exercise | A | 7.41 | 40,000 | 296,400 | 40,000 | |
Jun 15 2016 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | Chief Executive Off ... | Option Exercise | A | 7.41 | 250,000 | 1,852,500 | 250,000 | |
Jun 15 2016 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | Chief Executive Off ... | Grant | A | 0.00 | 10,924 | 0 | 109,620 | 98.7 K to 109.6 K (+11.07 %) |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Carey Robert | Director | Option Exercise | A | 7.41 | 5,500 | 40,755 | 5,500 | |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Option Exercise | A | 7.41 | 5,500 | 40,755 | 5,500 | |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Scientific Of ... | Option Exercise | A | 7.41 | 175,000 | 1,296,750 | 175,000 | |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Scientific Of ... | Option Exercise | A | 6.09 | 3,375 | 20,554 | 3,375 | |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Scientific Of ... | Grant | A | 0.00 | 10,924 | 0 | 76,043 | 65.1 K to 76 K (+16.78 %) |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Petrov Andrei Vladimirovich | Director | Option Exercise | A | 7.41 | 5,500 | 40,755 | 5,500 | |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Option Exercise | A | 7.41 | 5,500 | 40,755 | 5,500 | |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Option Exercise | A | 7.41 | 5,500 | 40,755 | 5,500 | |
Jun 14 2016 | ARGS | ARGOS THERAPEUTICS ... | Krol Igor | Director | Option Exercise | P | 7.41 | 11,000 | 81,510 | 11,000 | |
Apr 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Grant | A | 0.00 | 1,757 | 0 | 46,857 | 45.1 K to 46.9 K (+3.90 %) |
Apr 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Carey Robert | Director | Grant | A | 0.00 | 1,757 | 0 | 1,757 | 0 to 1.8 K |
Apr 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Petrov Andrei Vladimirovich | Director | Grant | A | 0.00 | 1,660 | 0 | 6,660 | 5 K to 6.7 K (+33.20 %) |
Apr 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Vinogradov Alexey Alexandrovic ... | Director | Grant | A | 0.00 | 1,367 | 0 | 3,367 | 2 K to 3.4 K (+68.35 %) |
Apr 04 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Grant | A | 0.00 | 1,367 | 0 | 1,367 | 0 to 1.4 K |
Apr 04 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Grant | A | 0.00 | 2,734 | 0 | 2,734 | 0 to 2.7 K |
Mar 16 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Option Exercise | P | 5.35 | 1,339,151 | 7,164,458 | 1,339,151 | |
Mar 16 2016 | ARGS | ARGOS THERAPEUTICS ... | Pharmstandard International S. ... | 10% Owner | Buy | P | 0.00 | 1,785,534 | 0 | 7,769,083 | 6 M to 7.8 M (+29.84 %) |
Mar 16 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Option Exercise | P | 5.35 | 661,309 | 3,538,003 | 661,309 | |
Mar 16 2016 | ARGS | ARGOS THERAPEUTICS ... | van Deventer Sander | Director | Buy | P | 0.00 | 881,745 | 0 | 3,331,889 | 2.5 M to 3.3 M (+35.99 %) |
Mar 16 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Option Exercise | P | 5.35 | 137,773 | 737,086 | 137,773 | |
Mar 16 2016 | ARGS | ARGOS THERAPEUTICS ... | Birner Hubert | Director | Buy | P | 0.00 | 183,697 | 0 | 1,654,788 | 1.5 M to 1.7 M (+12.49 %) |
Apr 19 2016 | ARGS | ARGOS THERAPEUTICS ... | ALLEN LEE F MD PhD | Chief Medical Offic ... | Option Exercise | A | 10.97 | 16,628 | 182,409 | 16,628 | |
Jan 20 2016 | ARGS | ARGOS THERAPEUTICS ... | ALLEN LEE F MD PhD | Chief Medical Offic ... | Option Exercise | A | 2.16 | 300,000 | 648,000 | 300,000 | |
Jan 12 2016 | ARGS | ARGOS THERAPEUTICS ... | MIESOWICZ FREDERICK | COO | Grant | A | 0.00 | 35,554 | 0 | 36,843 | 1.3 K to 36.8 K (+2,758.26 %) |
Jan 12 2016 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Grant | A | 0.00 | 32,709 | 0 | 33,709 | 1,000 to 33.7 K (+3,270.90 %) |
Jan 12 2016 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Scientific Of ... | Grant | A | 0.00 | 48,604 | 0 | 63,117 | 14.5 K to 63.1 K (+334.90 %) |
Jan 12 2016 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | CEO | Grant | A | 0.00 | 90,401 | 0 | 96,694 | 6.3 K to 96.7 K (+1,436.53 %) |
Jan 12 2016 | ARGS | ARGOS THERAPEUTICS ... | Harrelson Lori R. | Vice President of F ... | Grant | A | 0.00 | 28,125 | 0 | 30,005 | 1.9 K to 30 K (+1,496.01 %) |
Dec 17 2015 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Buy | P | 1.83 | 250 | 458 | 500 | 250 to 500 (+100.00 %) |
Dec 17 2015 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | CEO | Buy | P | 2.50 | 5,000 | 12,486 | 10,500 | 5.5 K to 10.5 K (+90.91 %) |
Dec 17 2015 | ARGS | ARGOS THERAPEUTICS ... | Petrov Andrei Vladimirovich | Director | Buy | P | 1.80 | 5,000 | 9,000 | 5,000 | 0 to 5 K |
Dec 16 2015 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Buy | P | 2.15 | 50 | 107 | 250 | 200 to 250 (+25.00 %) |
Dec 16 2015 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Buy | P | 2.15 | 100 | 215 | 200 | 100 to 200 (+100.00 %) |
Dec 16 2015 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Buy | P | 2.15 | 100 | 215 | 100 | 0 to 100 |
Dec 16 2015 | ARGS | ARGOS THERAPEUTICS ... | Vinogradov Alexey Alexandrovic ... | Director | Buy | P | 2.15 | 2,000 | 4,300 | 2,000 | 0 to 2 K |
Dec 03 2015 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | CEO | Buy | P | 3.89 | 1,000 | 3,889 | 6,293 | 5.3 K to 6.3 K (+18.89 %) |
Nov 25 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 4.25 | 5,000 | 21,250 | 45,100 | 40.1 K to 45.1 K (+12.47 %) |
Nov 25 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 4.30 | 5,000 | 21,500 | 40,100 | 35.1 K to 40.1 K (+14.25 %) |
Nov 23 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 4.15 | 10,000 | 41,511 | 35,100 | 25.1 K to 35.1 K (+39.84 %) |
Nov 23 2015 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | CEO | Buy | P | 4.08 | 1,000 | 4,080 | 6,500 | 5.5 K to 6.5 K (+18.18 %) |
Sep 21 2015 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Option Exercise | P | 6.21 | 20,000 | 124,200 | 20,000 | |
Sep 04 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 6.31 | 6,000 | 37,843 | 25,100 | 19.1 K to 25.1 K (+31.41 %) |
Sep 04 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 6.22 | 6,000 | 37,342 | 19,100 | 13.1 K to 19.1 K (+45.80 %) |
Sep 02 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 6.26 | 5,000 | 31,318 | 13,100 | 8.1 K to 13.1 K (+61.73 %) |
Aug 27 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 5.80 | 5,000 | 29,024 | 8,100 | 3.1 K to 8.1 K (+161.29 %) |
Aug 27 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Buy | P | 4.73 | 3,100 | 14,654 | 3,100 | 0 to 3.1 K |
Aug 27 2015 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Buy | P | 6.09 | 100 | 609 | 1,000 | 900 to 1,000 (+11.11 %) |
Aug 27 2015 | ARGS | ARGOS THERAPEUTICS ... | Winterbottom Joan | Chief Human Resourc ... | Buy | P | 6.10 | 900 | 5,490 | 900 | 0 to 900 |
Aug 27 2015 | ARGS | ARGOS THERAPEUTICS ... | Nicolette Charles A. | Chief Scientific Of ... | Buy | P | 6.45 | 5,000 | 32,250 | 13,130 | 8.1 K to 13.1 K (+61.50 %) |
Aug 26 2015 | ARGS | ARGOS THERAPEUTICS ... | Lamarre Jean | Director | Buy | P | 6.14 | 2,500 | 15,353 | 2,500 | 0 to 2.5 K |
Aug 21 2015 | ARGS | ARGOS THERAPEUTICS ... | Abbey Jeffrey D | CEO | Buy | P | 4.75 | 5,500 | 26,149 | 5,500 | 0 to 5.5 K |
Jun 19 2015 | ARGS | ARGOS THERAPEUTICS ... | Van Holle Philippe Marie Marce ... | Director | Option Exercise | A | 7.80 | 5,500 | 42,900 | 5,500 |